The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
M LebwohlA DeodharChristopher Ernest Maitland GriffithsM A MenterD PoddubnyyW BaoV JehlK MarfoP PrimatestaA SheteV TrivediP J MeasePublished in: The British journal of dermatology (2021)
In this large safety analysis, the risk of malignancy was low for up to 5 years of secukinumab treatment. These data support the long-term use of secukinumab in these indications.